Last reviewed · How we verify
ACE393
ACE393 is a therapeutic vaccine designed to stimulate immune responses against cancer cells by targeting tumor-associated antigens.
ACE393 is a therapeutic vaccine designed to stimulate immune responses against cancer cells by targeting tumor-associated antigens. Used for Cancer (specific indication under investigation in phase 2).
At a glance
| Generic name | ACE393 |
|---|---|
| Also known as | Campylobacter jejuni |
| Sponsor | TD Vaccines A/S |
| Drug class | Cancer vaccine |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
As a cancer vaccine in development by TD Vaccines, ACE393 likely works by activating the patient's own immune system to recognize and attack cancer cells expressing specific tumor antigens. The vaccine approach aims to generate durable cellular and humoral immune responses that can control or eliminate malignant cells.
Approved indications
- Cancer (specific indication under investigation in phase 2)
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |